ORG-25935

ORG-25935 is a drug that acts as a serotonin reuptake inhibitor, and was developed for the treatment of depression and anxiety disorders. It was developed by Organon International, a pharmaceutical company based in the Netherlands.

History

ORG-25935 was first synthesized by Organon International in the early 2000s. The drug was developed as a potential treatment for depression and anxiety disorders, due to its ability to inhibit the reuptake of serotonin, a neurotransmitter that is often imbalanced in individuals with these conditions.

Mechanism of Action

ORG-25935 works by inhibiting the reuptake of serotonin, a neurotransmitter that is involved in mood regulation. By preventing the reuptake of serotonin, ORG-25935 increases the amount of serotonin available in the brain, which can help to alleviate symptoms of depression and anxiety.

Clinical Trials

Clinical trials for ORG-25935 were conducted in the mid-2000s. However, the drug did not progress beyond Phase II trials, and its development was discontinued.

See Also

• Organon International
• Serotonin reuptake inhibitor
• Depression
• Anxiety disorders

References

ORG-25935 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski